News and Resources
MHRP, WRAIR Begin New Phase 2 Clinical Trial of Ebola Vaccine Regimens
The Walter Reed Army Institute of Research (WRAIR) today announced the initiation of a Phase 2 clinical trial to evaluate the safety and immunogenicity of a prime-boost Ebola vaccine regimen in both healthy and HIV-infected study volunteers. This study includes two vaccine candidates, Ad26.ZEBOV from Crucell Holland B.V., one of…
New Ebola vaccine study begins in Nigeria
MHRP began a new Ebola vaccine study last week at its site in Abuja, Nigeria in collaboration with the Nigerian Ministries of Defence and Health. The vaccine used in the study (RV429) is the monovalent chimpanzee adenovirus Type 3 (ChAd3) candidate developed at the NIAID and being developed by GlaxoSmithKline…